Genmab — November 2016
-
-
Solsen fik du mit post om PD1-hæmmer ? BMS vs Dara+Tecentriq fra Roche? Jeg tænker, hvis Dara+Tecq kan nå at blande sig, hvad kan det så betyde i brand og bekræftigelsen i at Dara virker uden for MM. Kan vi så ikke godt formode et bud på hele butikken - og i bekræftende fald vil et bud formodentlig falde inden H2 2017?
-
Studie afslører problemer med lovende immunterapier
Et nyt studie peger på, at en lovende type immunterapi mod kræft kendt som checkpoint-hæmmere kan medføre store bivirkningsproblemer for visse patienter. To patienter er døde af inflammation i hjertet efter behandling med en kombination af to midler fra Bristol-Myers Squibb.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind